Pasithea Therapeutics Reports Positive Trial Results for PAS-004

Pasithea Therapeutics shares are trading higher after the company reported positive interim pharmacodynamic results from its ongoing Phase 1 clinical trial of PAS-004, demonstrating robust target engagement and tumor reduction in pancreatic cancer.